Literature DB >> 8825571

Canine osteosarcoma: amputation and chemoimmunotherapy.

E G MacEwen1, I D Kurzman.   

Abstract

Canine osteosarcoma is a highly metastatic cancer commonly seen in large breed dogs. At the time of diagnosis, approximately 90% to 95% of the dogs have established micrometastases. Dogs undergoing amputation alone have a median survival time of 3 to 4 months. Amputation followed by cisplatin chemotherapy increases median survival times to 9 to 11 months. When dogs are treated with amputation and cisplatin, followed by immunotherapy (with liposome-encapsulated muramyl tripeptide phosphatidylethanolamine), median survival times increase to 14.4 months, the longest reported median survival time for dogs with osteosarcoma treated by amputation and any form of adjuvant therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8825571     DOI: 10.1016/s0195-5616(96)50011-2

Source DB:  PubMed          Journal:  Vet Clin North Am Small Anim Pract        ISSN: 0195-5616            Impact factor:   2.093


  5 in total

1.  Canine osteosarcoma cells exhibit basal accumulation of multiple chaperone proteins and are sensitive to small molecule inhibitors of GRP78 and heat shock protein function.

Authors:  Daphne R Mattos; Marcus A Weinman; Xuemei Wan; Cheri P Goodall; Jeffrey D Serrill; Kerry L McPhail; Milan Milovancev; Shay Bracha; Jane E Ishmael
Journal:  Cell Stress Chaperones       Date:  2022-03-04       Impact factor: 3.827

Review 2.  What do we know about canine osteosarcoma treatment? Review.

Authors:  M Szewczyk; R Lechowski; K Zabielska
Journal:  Vet Res Commun       Date:  2014-11-26       Impact factor: 2.459

Review 3.  Comparative review of human and canine osteosarcoma: morphology, epidemiology, prognosis, treatment and genetics.

Authors:  Siobhan Simpson; Mark David Dunning; Simone de Brot; Llorenç Grau-Roma; Nigel Patrick Mongan; Catrin Sian Rutland
Journal:  Acta Vet Scand       Date:  2017-10-24       Impact factor: 1.695

4.  Gabapentin for phantom limb pain after amputation in pediatric oncology: a systematic review protocol.

Authors:  Shuang Jiang; Meng-Meng Zhou; Rong Xia; Jing-Hui Bai; Li-Hui Yan
Journal:  Syst Rev       Date:  2021-01-13

5.  Proteomic Assessment of Extracellular Vesicles from Canine Tissue Explants as a Pipeline to Identify Molecular Targets in Osteosarcoma: PSMD14/Rpn11 as a Proof of Principle.

Authors:  Anita K Luu; Mia Cadieux; Mackenzie Wong; Rachel Macdonald; Robert Jones; Dongsic Choi; Michelle Oblak; Brigitte Brisson; Scott Sauer; James Chafitz; David Warshawsky; Geoffrey A Wood; Alicia M Viloria-Petit
Journal:  Int J Mol Sci       Date:  2022-03-17       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.